Dose Escalation Study of CyberKnife® SBRT Boost for Patients With Unresectable Locally Advanced Pancreatic Cancer

NATerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 16, 2018

Study Completion Date

May 16, 2018

Conditions
Pancreatic Carcinoma Non-resectable
Interventions
RADIATION

CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost

Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.

Trial Locations (1)

K1H8L6

The Ottawa Hospital Cancer Centre, Ottawa

All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER